LUPIN ARM LAUNCHES LUFORBEC IN GERMANY USED FOR COPD
Lupin’s wholly-owned subsidiary, Hormosan Pharma GmbH (Hormosan), has launched Luforbec 100/6 in Germany. Luforbec is a fixed-dose combination of beclometasone dipropionate and formoterol fumarate dihydrate, indicated for the long-term, once-daily maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Luforbec is a generic version of Foster 100/6, which is marketed by AstraZeneca. The launch … Read more